See more. Connect more. Create more value.
One of the biggest challenges many leaders face is:
How do I stay true to our mission to help patients but at the same time ensure shareholder value?
HaywoodMAP helps biotech and pharmaceutical leaders find strategies that allow both to happen.
What Makes HaywoodMAP Different?
HaywoodMAP brings broad visibility across markets, portfolios and the asset lifecycle to uncover connections that might otherwise be missed.
Innovation does not always require creating something entirely new…one thing I’ve learned is that the best answer to a question often comes from connecting two ideas that appear, at first, to be unrelated.
A pricing opportunity in Japan can lift the global value of an asset. Success in China can positively impact the global P&L. The right formulation decision early in asset development can keep you from leaking value during the lifecycle. Opportunities like these come from broad visibility.
A connected perspective is what makes HaywoodMAP different: we help leadership teams see more of the choices that shape both patient impact and shareholder value.
From Possibility to Choice
Broad visibility can reveal possibilities, but not every possibility is worth pursuing. There are always more things you could do with an asset than you have the money or time to achieve.
HaywoodMAP helps leadership teams determine where opportunities exist across markets, when they matter across the portfolio and lifecycle, and whether to invest relative to other choices.
The P&L provides an important test. It connects patient opportunity and strategic possibility to the investment and sustainable return required to earn continued support from leadersip and shareholders.
The goal is to find the choices that allow teams to serve more patients while creating sustainable shareholder value.
I use that perspective across four parts of an asset's journey: shaping the opportunity, securing its value, scaling patient reach and sustaining value over time.
Experience Behind the Perspective
Nearly 30 years across markets, functions, portfolios and the asset lifecycle.
Matt Haywood's pharmaceutical career spans sales, managed care, policy and advocacy, brand marketing, payer strategy and global market access, with experience across both U.S. and international markets. Most recently, he served as Vice President of International Market Access and Pricing for Oncology at AbbVie, with responsibility spanning more than 40 markets.
His experience extends upstream into portfolio and asset strategy, including investment prioritization, clinical endpoint optimization, indication sequencing and accelerated launch strategies, and downstream through pricing, reimbursement, global launch and lifecycle management.
That breadth is the foundation of HaywoodMAP's connected perspective: seeing across markets and across the portfolio and asset lifecycle to uncover possibilities that might otherwise be missed.
Start a Conversation
Have an asset, market or portfolio question where the path forward isn't obvious?
HaywoodMAP works with biotech and pharmaceutical leaders on complex choices across markets and across the portfolio and asset lifecycle.
Let's explore what might be possible.